SATIVEX Trademark

Trademark Overview


On Wednesday, July 17, 2019, a trademark application was filed for SATIVEX with the United States Patent and Trademark Office. The USPTO has given the SATIVEX trademark a serial number of 79266020. The federal status of this trademark filing is ABANDONED - AFTER EX PARTE APPEAL as of Monday, January 23, 2023. This trademark is owned by GW Pharma Limited. The SATIVEX trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical and veterinary preparations, namely, for use in treating pain, neuropathic pain, cancer pain, multiple sclerosis, spinal cord injury, bladder dysfunction, peripheral neuropathy, spasticity, cancer and cancer symptoms, perioperative pain, rheumatoid arthritis, inflammatory bowel disease, ulcerative colitis, hypoxic-ischaemic encephalopathy, symptoms of neurogenic disorders, movement disorders, essential tremors, psychotic disorders, diseases of the central nervous system, stroke and head injuries, motion sickness and chemically induced sickness, spasticity, psychiatric illnesses, post-traumatic stress disorder, neurodegenerative diseases, metabolic disorders, obesity, obesity associated with Type II Diabetes, bulimia, schizophrenia, Crohn's disease, Alzheimer's disease, bone disorders, inflammatory disorders, sleep and sleep disorders, and drug, alcohol, and nicotine abuse; pharmaceutical preparations for the treatment of neurological conditions and diseases; herbs for me...
sativex

General Information


Serial Number79266020
Word MarkSATIVEX
Filing DateWednesday, July 17, 2019
Status603 - ABANDONED - AFTER EX PARTE APPEAL
Status DateMonday, January 23, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesPharmaceutical and veterinary preparations, namely, for use in treating pain, neuropathic pain, cancer pain, multiple sclerosis, spinal cord injury, bladder dysfunction, peripheral neuropathy, spasticity, cancer and cancer symptoms, perioperative pain, rheumatoid arthritis, inflammatory bowel disease, ulcerative colitis, hypoxic-ischaemic encephalopathy, symptoms of neurogenic disorders, movement disorders, essential tremors, psychotic disorders, diseases of the central nervous system, stroke and head injuries, motion sickness and chemically induced sickness, spasticity, psychiatric illnesses, post-traumatic stress disorder, neurodegenerative diseases, metabolic disorders, obesity, obesity associated with Type II Diabetes, bulimia, schizophrenia, Crohn's disease, Alzheimer's disease, bone disorders, inflammatory disorders, sleep and sleep disorders, and drug, alcohol, and nicotine abuse; pharmaceutical preparations for the treatment of neurological conditions and diseases; herbs for medicinal purposes; medicinal herbs; medicinal oils; medicinal infusions, each of the foregoing for use in treating pain, neuropathic pain, cancer pain, multiple sclerosis, spinal cord injury, bladder dysfunction, peripheral neuropathy, spasticity, cancer and cancer symptoms, perioperative pain, rheumatoid arthritis, inflammatory bowel disease, ulcerative colitis, hypoxic-ischaemic encephalopathy, symptoms of neurogenic disorders, movement disorders, essential tremors, psychotic disorders, diseases of the central nervous system, stroke and head injuries, motion sickness and chemically induced sickness, spasticity, psychiatric illnesses, post-traumatic stress disorder, neurodegenerative diseases, metabolic disorders, obesity, obesity associated with Type II Diabetes, bulimia, schizophrenia, Crohn's disease, Alzheimer's disease, bone disorders, inflammatory disorders, sleep and sleep disorders, and drug, alcohol, and nicotine abuse; pure extracts of medicinal plants and herbs for pharmaceutical use; foodstuffs for medicinal purposes; herb teas for medicinal purposes; pharmaceutical preparations for the treatment of pain, neuropathic pain, cancer pain, multiple sclerosis, spinal cord injury, bladder dysfunction, peripheral neuropathy, spasticity, oncology, cancer symptoms, psychiatric illnesses, neurodegenerative diseases and metabolic disorders; plant extracts for pharmaceutical purposes

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, September 4, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameGW Research Limited
Party Type11 - New Owner Before Publication
Legal Entity Type98 - Unknown
AddressGB

Party NameGW Pharma Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressGB

Trademark Events


Event DateEvent Description
Tuesday, July 28, 2020ASSIGNED TO EXAMINER
Thursday, August 22, 2019SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
Monday, August 26, 2019LIMITATION FROM ORIGINAL APPLICATION ENTERED
Wednesday, September 4, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, September 10, 2019APPLICATION FILING RECEIPT MAILED
Saturday, September 21, 2019ASSIGNED TO EXAMINER
Thursday, July 30, 2020NON-FINAL ACTION WRITTEN
Saturday, February 13, 2021NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Friday, July 31, 2020NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Wednesday, August 12, 2020NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
Friday, August 14, 2020NON-FINAL ACTION WRITTEN
Saturday, August 15, 2020NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Wednesday, September 9, 2020REFUSAL PROCESSED BY MPU
Thursday, September 10, 2020NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Saturday, September 26, 2020REFUSAL PROCESSED BY IB
Wednesday, January 27, 2021NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Wednesday, January 27, 2021NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Monday, May 3, 2021NOTIFICATION OF FINAL REFUSAL EMAILED
Monday, March 8, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, March 8, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, March 9, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, May 3, 2021FINAL REFUSAL WRITTEN
Monday, May 3, 2021FINAL REFUSAL E-MAILED
Wednesday, September 15, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, September 15, 2021TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Wednesday, September 15, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, September 15, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, November 3, 2021TEAS REQUEST FOR RECONSIDERATION RECEIVED
Wednesday, November 3, 2021EXPARTE APPEAL RECEIVED AT TTAB
Wednesday, November 3, 2021JURISDICTION RESTORED TO EXAMINING ATTORNEY
Wednesday, November 3, 2021EX PARTE APPEAL-INSTITUTED
Monday, November 8, 2021ASSIGNED TO LIE
Tuesday, November 9, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, November 9, 2021APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, November 9, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Saturday, November 20, 2021NEW REPRESENTATIVE AT IB RECEIVED
Monday, January 3, 2022NON-FINAL ACTION WRITTEN
Monday, January 3, 2022NON-FINAL ACTION E-MAILED
Monday, January 3, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, July 5, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, July 5, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, August 17, 2022NOTIFICATION OF SUBSEQUENT FINAL EMAILED
Wednesday, July 6, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, August 17, 2022SUBSEQUENT FINAL REFUSAL WRITTEN
Wednesday, August 17, 2022SUBSEQUENT FINAL EMAILED
Thursday, January 5, 2023INTERNATIONAL REGISTRATION RENEWED
Friday, December 9, 2022EXPARTE APPEAL DISMISSED - FAILURE TO FILE BRIEF
Monday, March 11, 2024FINAL DECISION TRANSACTION PROCESSED BY IB
Monday, January 23, 2023ABANDONMENT - AFTER EX PARTE APPEAL
Friday, February 10, 2023ABANDONMENT NOTICE MAILED - AFTER EX PARTE APPEAL
Monday, January 23, 2023EXPARTE APPEAL TERMINATED
Friday, February 10, 2023ABANDONMENT NOTICE MAILED - AFTER EX PARTE APPEAL
Saturday, February 10, 2024FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Monday, February 12, 2024FINAL DISPOSITION NOTICE SENT TO IB
Friday, May 31, 2024CHANGE OF OWNER RECEIVED FROM IB